Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07315087) titled 'CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases' on Dec. 18, 2025.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Condition:
SLE - Systemic Lupus Erythematosus
SSc-Systemic Sclerosis
IIM- Idiopathic Inflammatory Myopathies
ANCA Associated Vasculitis (AAV)
Connective Tissue Disease-Associated Thrombocytopenia
SLE-ITP
Intervention:
Biological: QT-019C
Recruitment Status:...